Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
about
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are alteredVenous thromboembolism in malignant gliomasThe therapeutic management of bleeding and thrombotic disorders complicating CNS malignancies.A critical balance: managing coagulation in patients with glioma.Tissue factor associates with survival and regulates tumour progression in osteosarcoma.Tissue Factor promotes breast cancer stem cell activity in vitro.Tumors, ticks and tissue factor.Human Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in gliomaProtease-activated receptors mediate crosstalk between coagulation and fibrinolysis.Brain neoplasms and coagulation-lessons from heterogeneity.Tissue factor in tumor microenvironment: a systematic reviewUpregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma.Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells.Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response.The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma.Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.Targeting JNK for therapeutic depletion of stem-like glioblastoma cellsComplex oncogenic signaling networks regulate brain tumor-initiating cells and their progenies: pivotal roles of wild-type EGFR, EGFRvIII mutant and hedgehog cascades and novel multitargeted therapies.Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant gliomaPI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition.Immunohistochemical classification of primary and secondary glioblastomas.Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.Tissue factor and cell signalling in cancer progression and thrombosis.Interleukins in glioblastoma pathophysiology: implications for therapy.Glioblastoma complicated by fatal malignant acute ischemic stroke: MRI finding to assist in tricky surgical decision.Cancer-associated pathways and biomarkers of venous thrombosis.TF/FVIIa/PAR2 promotes cell proliferation and migration via PKCα and ERK-dependent c-Jun/AP-1 pathway in colon cancer cell line SW620.Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor.Prognostic values of tissue factor and its alternatively splice transcripts in human gastric cancer tissues.Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma.P14ARF suppresses tumor-induced thrombosis by regulating the tissue factor pathway.Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft modelCoagulation-related gene expression profile in glioblastoma is defined by molecular disease subtype.Identifying radiographic specificity for phosphatase and tensin homolog and epidermal growth factor receptor changes: a quantitative analysis of glioblastomas.Characterization of a FOXG1:TLE1 transcriptional network in glioblastoma initiating cells.Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles.Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer.Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
P2860
Q27015045-723BE310-38D9-49ED-8A3A-E90327B4D6FBQ30436810-AB65968B-CBF9-4127-B20A-3FB36FB56323Q33402515-F258CD96-DBFB-43E6-B77F-740AEFFDFF99Q33431673-0B8D4B8C-0E19-42A6-A95E-E7668812E135Q33672303-55FB4C58-5CC2-4CB3-9C2E-76102F1E7E06Q33688466-8218FEB7-CE29-41A6-9D37-5DAD0C243EB0Q33710071-8CE10C12-5B9B-4D27-8AAF-BB6197297C93Q34052754-56E4038A-14DE-45F5-A5B5-DF3BCF1E48CCQ34101190-3550296E-E078-4D44-B826-3C3DEF37B747Q34450747-38928D00-9E52-4EE7-8841-2DEAB4378496Q34463432-D457ED8A-12C0-4736-93D4-5E98DB4BB300Q34544801-D0B29CA8-7297-4021-BBBE-C631FFF970BBQ35005521-C00C83FE-A946-474C-BA06-E4CE4AD75EA3Q35164701-A9735F77-73B4-46B1-9894-3596A0D838EBQ35729814-EE177F33-A7DD-40A8-A630-9D81D753133CQ35766780-B68B2F37-6301-458A-B616-FF667C32C7D9Q35967008-E9BE2736-7DCF-43A5-A056-685953F5751FQ36088261-93047F6C-1DDE-4F73-8323-5C8029F480CEQ36103845-753CA098-01C0-473E-8416-80D7616D9647Q36280796-47809D3D-F554-492B-A3E8-E09B6948EA07Q36808787-D4E51CF7-E6DE-44FD-AF28-AB9F1C4A34B3Q36899519-C9AA1F4A-A2ED-44EC-9AF9-4038833A72F2Q37459120-29A07691-E60E-4A1A-86F4-69B560014703Q37628002-A6C9E932-29F6-44C3-85CD-97AF5B393F3CQ37903955-3C90E5B1-B422-4D3B-9F85-1E113FC2FAD7Q38051761-8EB1CF0E-4DEB-4B5B-B951-397C4C263910Q38535581-15F97DD3-EA78-4BCA-B3DE-07168BE0CE69Q38642557-4791B30B-A3CB-40C5-A0BF-49902F0109BCQ39160971-B75532F8-6488-433F-B583-771419F22A8AQ39250608-09F404FD-FC01-486D-A669-559643B941ACQ41593075-2942DCD6-752D-48EC-A335-EBF327924736Q41709078-6EABF5E3-9A91-4E67-BC27-8090BAC8B3A1Q41864823-7F62B4F9-3B8C-479D-86C6-CBBB2B001869Q42364589-242C4870-84A4-47EC-9243-9D18614779BFQ44444427-8C14361E-0A15-4166-A6C2-255F0D7C3A71Q47584260-95BEFB11-6F77-4377-9CFE-0C6D1DCA8631Q47874491-1E066648-471D-431E-8007-886229E93DECQ53781843-06D38A99-4D76-4F0B-A961-3095789D2C39Q54967623-9C777363-7836-4E0B-AE06-9C1936F07E89Q55457269-1AECD53B-2015-46B3-A1B3-A5845E660CC7
P2860
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epidermal growth factor recept ...... in-1 transcriptional activity.
@en
Epidermal growth factor recept ...... in-1 transcriptional activity.
@nl
type
label
Epidermal growth factor recept ...... in-1 transcriptional activity.
@en
Epidermal growth factor recept ...... in-1 transcriptional activity.
@nl
prefLabel
Epidermal growth factor recept ...... in-1 transcriptional activity.
@en
Epidermal growth factor recept ...... in-1 transcriptional activity.
@nl
P2093
P2860
P1433
P1476
Epidermal growth factor recept ...... in-1 transcriptional activity.
@en
P2093
Carol Tucker-Burden
Daniel J Brat
Donald L Durden
Jeffrey J Olson
Nigel Mackman
Vladimir E Belozerov
P2860
P304
P356
10.1158/0008-5472.CAN-08-1547
P407
P577
2009-03-10T00:00:00Z